Form 8-K - Current report:
SEC Accession No. 0000950170-25-109932
Filing Date
2025-08-19
Accepted
2025-08-19 07:00:27
Documents
12
Period of Report
2025-08-19
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aldx-20250819.htm   iXBRL 8-K 59695
2 EX-99.1 aldx-ex99_1.htm EX-99.1 27102
3 GRAPHIC img112526854_0.jpg GRAPHIC 49911
  Complete submission text file 0000950170-25-109932.txt   275635

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aldx-20250819.xsd EX-101.SCH 30863
14 EXTRACTED XBRL INSTANCE DOCUMENT aldx-20250819_htm.xml XML 4712
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 251229624
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)